膵臓がんの2030年までの市場予測：治療タイプ、診断ツール、エンドユーザー、地域別の世界分析

Stratistics MRCによると、世界の膵臓がん市場は2024年に34億2,000万米ドルを占め、予測期間中にCAGR 17.8％で成長し、2030年には91億3,000万米ドルに達すると予測されています。

膵臓がんは、胃の後ろに位置する臓器である膵臓の組織に発生する悪性新生物です。膵臓の細胞の異常で制御不能な増殖が特徴で、腫瘍の形成につながります。膵臓がんは早期発見が難しいことが多く、死亡率の高さの一因となっています。症状は病気がかなり進行するまで現れないことがあり、腹痛、黄疸、原因不明の体重減少、消化器系の問題などがあります。

アメリカがん協会によると、2023年には約64,050人が膵臓がんと診断され、約50,550人が膵臓がんで死亡すると推定されています。

患者支援団体の積極的関与

患者支援団体の積極的な関与は、認知度の向上、研究イニシアチブの推進、政策変更への影響力によって、膵臓がん市場の強化に極めて重要な役割を果たしています。これらの団体は、患者の声を増幅させ、膵がん研究のための資金やリソースを増やすためのロビー活動を行うなど、患者の強力な支持者としての役割を果たしています。患者支援団体は、その活動を通じて、膵臓がんに対する一般の人々の認識を高めるだけでなく、早期発見法や革新的な治療法に対する支持を結集しています。さらに、研究者、医療従事者、製薬企業間の協力を促進し、新規治療法の開発を加速させ、患者の転帰を改善しています。

高い治療費

高額な治療費は、患者にとってアクセスへの大きな障壁となり、膵がん市場の大きな妨げとなっています。膵がんは複雑な疾患であるため、治療期間が長期化することが多く、患者やヘルスケアシステムの経済的負担をさらに悪化させています。しかし、高額な医療費は、患者が適時に治療を受けることを躊躇させるだけでなく、医療予算を圧迫し、新たな治療法の研究開発へのリソースの利用を制限しています。

手術技術の向上

手術手技の向上は、より効果的な治療選択肢と患者の転帰の改善をもたらし、膵がん市場を大きく活性化しています。腹腔鏡手術やロボット支援手術などの低侵襲手術は、従来の開腹手術に比べて術後合併症の減少、回復時間の短縮、患者の快適性の向上をもたらしています。これらの進歩により、外科医は複雑な膵切除術をより正確に、周辺組織へのダメージを最小限に抑えて行うことが可能となり、患者の生存率やQOLの改善につながります。

早期発見のためのバイオマーカーの欠如

早期発見のための信頼性の高いバイオマーカーが存在しないことは、膵がん市場の発展にとって大きな障害となっています。バイオマーカーが早期診断に役立つ他のがんとは異なり、膵がんは進行期に至るまで無症状のままであることが多く、タイムリーな発見が困難です。その結果、患者はすでに転移している状態で診断されることが多く、治療の選択肢が著しく制限され、全生存率が低下します。効果的なバイオマーカーがないため、臨床医は膵臓がんを治療可能な初期段階で特定する手段を欠き、標的治療や個別化治療アプローチの開発を妨げています。

COVID-19の影響：

パンデミックは、革新的治療への緊急性を高め、研究努力を加速させたが、同時に患者の治療や臨床試験にも支障をきたしました。COVID-19の管理にヘルスケア資源が転用されたことで、がん医療サービスが逼迫し、多くの膵臓がん患者の診断と治療開始が遅れることになった。必要のない医療処置が制限され、患者の医療機関への受診が減少した結果、スクリーニングや診断処置が減少し、膵臓がんの診断の見落としや遅れの原因となる可能性があった。しかし、パンデミックは遠隔医療や遠隔モニタリングソリューションの採用を促し、COVID-19の制限がもたらす課題の中で、患者のケアや臨床試験への参加を継続する道を提供しました。

予測期間中、放射線療法分野が最大になる見込み

予測期間中、放射線療法分野が最大となる見込みです。この治療法では、高エネルギーの放射線を用いてがん細胞を破壊し、腫瘍を縮小させる。末期診断や腫瘍の位置によって外科手術の選択肢が制限されがちな膵臓がんの場合、放射線療法が重要な治療手段として浮上してくる。放射線療法は、術前に腫瘍を縮小させて外科的切除に対応しやすくしたり、術後に残存するがん細胞を狙い撃ちしたりするために用いられます。さらに、放射線療法はその効果を最大限にするために、化学療法などの他の治療法と併用されることも多いです。

磁気共鳴画像法（MRI）分野は予測期間中に最も高いCAGRを示すと予想されます。

磁気共鳴画像法（MRI）分野は、予測期間中に最も高いCAGRが見込まれます。MRIは軟部組織のコントラストに優れ、膵臓とその周辺構造を正確に可視化できるため、膵腫瘍の早期発見と正確な病期分類が容易になります。MRIは非侵襲的で電離放射線を使用しないため、疾患の進行や治療効果のモニタリングに特に有利です。さらに、拡散強調画像や動的造影MRIなどの進歩により、膵がん検出の感度と特異度がさらに向上しています。

最大のシェアを占める地域

アジア太平洋地域は、推定期間中、膵がん市場で最大のシェアを占めると推定されます。効果的な償還政策は、化学療法、放射線療法、外科的介入など、高額ではあるが救命の可能性がある治療への患者の幅広いアクセスを促進することができます。医療費が確実にカバーされることで、こうした政策は医療提供者に先進技術や治療法の導入を促し、膵がん患者に対するケアの質の地域的な向上を促進します。さらに、有利な償還政策は、製薬会社が地域特有の医療ニーズに合わせた研究開発に投資する動機付けとなり、新規治療法や診断ツールの導入につながります。

CAGRが最も高い地域：

アジア太平洋地域は、推定・予測期間中に収益性の高い成長を遂げると予測されています。各国政府は、厳しい規制の枠組みを通じて、製薬企業が膵がん治療法の開発において高い有効性と安全性の基準を遵守することを保証しています。規制機関は新治療法の承認プロセスを迅速化し、アジア太平洋地域の患者が最先端の治療法にタイムリーにアクセスできるよう取り組んでいます。さらに、規制は市場関係者間の透明性と公正な競争を促進し、最終的には競争力のある価格で幅広い治療選択肢を提供することで消費者の利益となります。こうした要素が、この地域の成長を後押ししています。

無料のカスタマイズ提供：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレーヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の膵臓がん市場：治療タイプ別

• 放射線治療
• 標的薬物療法
• 免疫療法
• 化学療法
• その他の治療タイプ

第6章 世界の膵臓がん市場：診断ツール別

• コンピュータ断層撮影（CT）スキャン
• 磁気共鳴画像（MRI）
• 陽電子放出断層撮影（PET）スキャン
• その他の診断ツール

第7章 世界の膵臓がん市場：エンドユーザー別

• 診断ラボ
• 病院
• その他のエンドユーザー

第8章 世界の膵臓がん市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイリング

• Celgene Corporation
• F. Hoffmann-La Roche AG
• Midatech Pharma PLC
• Eli Lilly and Company
• Sun BioPharma, Inc
• Oncolytics Biotech
• Clovis Oncology
• Polaris Pharmaceuticals, Inc
• Pharmacyte Biotech Inc
• Novartis International AG

List of Tables

• Table 1 Global Pancreatic Cancer Market Outlook, By Region (2022-2030) ($MN)
• Table 2 Global Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
• Table 3 Global Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
• Table 4 Global Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
• Table 5 Global Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
• Table 6 Global Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
• Table 7 Global Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
• Table 8 Global Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
• Table 9 Global Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
• Table 10 Global Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
• Table 11 Global Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
• Table 12 Global Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
• Table 13 Global Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
• Table 14 Global Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
• Table 15 Global Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
• Table 16 Global Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 17 North America Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
• Table 18 North America Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
• Table 19 North America Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
• Table 20 North America Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
• Table 21 North America Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
• Table 22 North America Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
• Table 23 North America Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
• Table 24 North America Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
• Table 25 North America Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
• Table 26 North America Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
• Table 27 North America Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
• Table 28 North America Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
• Table 29 North America Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
• Table 30 North America Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
• Table 31 North America Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
• Table 32 North America Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 33 Europe Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
• Table 34 Europe Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
• Table 35 Europe Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
• Table 36 Europe Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
• Table 37 Europe Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
• Table 38 Europe Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
• Table 39 Europe Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
• Table 40 Europe Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
• Table 41 Europe Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
• Table 42 Europe Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
• Table 43 Europe Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
• Table 44 Europe Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
• Table 45 Europe Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
• Table 46 Europe Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
• Table 47 Europe Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
• Table 48 Europe Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 49 Asia Pacific Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
• Table 50 Asia Pacific Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
• Table 51 Asia Pacific Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
• Table 52 Asia Pacific Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
• Table 53 Asia Pacific Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
• Table 54 Asia Pacific Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
• Table 55 Asia Pacific Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
• Table 56 Asia Pacific Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
• Table 57 Asia Pacific Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
• Table 58 Asia Pacific Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
• Table 59 Asia Pacific Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
• Table 60 Asia Pacific Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
• Table 61 Asia Pacific Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
• Table 62 Asia Pacific Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
• Table 63 Asia Pacific Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
• Table 64 Asia Pacific Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 65 South America Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
• Table 66 South America Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
• Table 67 South America Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
• Table 68 South America Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
• Table 69 South America Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
• Table 70 South America Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
• Table 71 South America Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
• Table 72 South America Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
• Table 73 South America Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
• Table 74 South America Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
• Table 75 South America Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
• Table 76 South America Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
• Table 77 South America Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
• Table 78 South America Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
• Table 79 South America Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
• Table 80 South America Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 81 Middle East & Africa Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
• Table 82 Middle East & Africa Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
• Table 83 Middle East & Africa Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
• Table 84 Middle East & Africa Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
• Table 85 Middle East & Africa Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
• Table 86 Middle East & Africa Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
• Table 87 Middle East & Africa Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
• Table 88 Middle East & Africa Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
• Table 89 Middle East & Africa Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
• Table 90 Middle East & Africa Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
• Table 91 Middle East & Africa Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
• Table 92 Middle East & Africa Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
• Table 93 Middle East & Africa Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
• Table 94 Middle East & Africa Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
• Table 95 Middle East & Africa Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
• Table 96 Middle East & Africa Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)

According to Stratistics MRC, the Global Pancreatic Cancer Market is accounted for $3.42 billion in 2024 and is expected to reach $9.13 billion by 2030 growing at a CAGR of 17.8% during the forecast period. Pancreatic cancer is a malignant neoplasm that originates in the tissues of the pancreas, an organ located behind the stomach. It is characterized by the abnormal and uncontrollable growth of cells in the pancreas, leading to the formation of tumors. Pancreatic cancer is often difficult to detect in its early stages, which contributes to its high mortality rate. Symptoms may not manifest until the disease has progressed significantly, and they can include abdominal pain, jaundice, unexplained weight loss, and digestive issues.

According to the America's Cancer Society for pancreatic cancer, about 64,050 people will be diagnosed with pancreatic cancer in 2023 and estimation of around 50,550 people will die of pancreatic cancer.

Market Dynamics:

Driver:

Active involvement of patient advocacy groups

Active involvement of patient advocacy groups is playing a pivotal role in enhancing the Pancreatic Cancer Market by fostering awareness, driving research initiatives, and influencing policy changes. These groups serve as powerful advocates for patients, amplifying their voices and lobbying for increased funding and resources for pancreatic cancer research. Through their efforts, patient advocacy groups are not only raising public awareness about the disease but also mobilizing support for early detection methods and innovative treatments. Moreover, they facilitate collaboration among researchers, healthcare professionals, and pharmaceutical companies, accelerating the development of novel therapies and improving patient outcomes.

Restraint:

High treatment costs

High treatment costs significantly hinder the Pancreatic Cancer Market by posing a substantial barrier to access for patients. The complexity of the disease often requires prolonged treatment periods, further exacerbating financial burdens on patients and healthcare systems. However, the high costs not only deter patients from seeking timely medical care but also strain healthcare budgets, limiting the availability of resources for research and development of new therapies.

Opportunity:

Improvements in surgical techniques

Improvements in surgical techniques are significantly enhancing the pancreatic cancer market by offering more effective treatment options and better patient outcomes. Minimally invasive procedures, such as laparoscopic and robotic-assisted surgeries, have reduced postoperative complications, shortened recovery times, and improved patient comfort compared to traditional open surgeries. These advancements enable surgeons to perform complex pancreatic resections with greater precision and minimal damage to surrounding tissues, leading to improved survival rates and quality of life for patients.

Threat:

Lack of biomarkers for early detection

The absence of reliable biomarkers for early detection poses a significant obstacle in advancing the pancreatic cancer market. Unlike some other cancers where biomarkers aid in early diagnosis, pancreatic cancer often remains asymptomatic until it reaches advanced stages, making timely detection challenging. Consequently, patients are often diagnosed when the disease has already metastasized, severely limiting treatment options and reducing overall survival rates. Without effective biomarkers, clinicians lack the tools to identify pancreatic cancer in its initial stages when it's more treatable, hindering the development of targeted therapies and personalized treatment approaches.

Covid-19 Impact:

While the pandemic heightened the urgency for innovative treatments and accelerated research efforts, it also disrupted patient care and clinical trials. The diversion of healthcare resources towards managing Covid-19 strained cancer care services, leading to delayed diagnoses and treatment initiation for many pancreatic cancer patients. Restrictions on non-essential medical procedures and reduced patient visits to healthcare facilities resulted in a decline in screening and diagnostic procedures, potentially causing missed or delayed diagnoses of pancreatic cancer. However, the pandemic also prompted the adoption of telemedicine and remote monitoring solutions, offering some avenues for continued patient care and clinical trial participation amidst the challenges posed by Covid-19 restrictions.

The Radiation Therapy segment is expected to be the largest during the forecast period

Radiation Therapy segment is expected to be the largest during the forecast period. This therapy involves the use of high-energy radiation to destroy cancer cells and shrink tumors. In the case of pancreatic cancer, where surgical options are often limited due to late-stage diagnosis or tumor location, radiation therapy emerges as a crucial treatment modality. It can be employed preoperatively to shrink tumors, making them more manageable for surgical removal, or postoperatively to target any remaining cancer cells. Additionally, radiation therapy is often combined with other treatment modalities like chemotherapy to maximize its effectiveness.

The Magnetic Resonance Imaging (MRI) segment is expected to have the highest CAGR during the forecast period

Magnetic Resonance Imaging (MRI) segment is expected to have the highest CAGR during the forecast period. MRI offers superior soft tissue contrast, allowing for precise visualization of the pancreas and surrounding structures, facilitating early detection and accurate staging of pancreatic tumors. Its non-invasive nature and lack of ionizing radiation make it particularly advantageous for monitoring disease progression and treatment response. Moreover, advancements such as diffusion-weighted imaging and dynamic contrast-enhanced MRI have further improved the sensitivity and specificity of pancreatic cancer detection.

Region with largest share:

Asia Pacific region is estimated to hold the largest share of the Pancreatic Cancer Market over the extrapolated period of time. Effective reimbursement policies can facilitate broader patient access to costly yet potentially life-saving treatments such as chemotherapy, radiation therapy, and surgical interventions. By ensuring that healthcare costs are covered, these policies encourage healthcare providers to adopt advanced technologies and therapies, driving regional improvements in the quality of care for pancreatic cancer patients. Moreover, favorable reimbursement policies can incentivize pharmaceutical companies to invest in research and development efforts tailored to the region's specific healthcare needs, leading to the introduction of novel therapies and diagnostic tools.

Region with highest CAGR:

Asia Pacific region is projected to estimate the profitable growth during the forecasted period. Through stringent regulatory frameworks, governments are ensuring that pharmaceutical companies adhere to high standards of efficacy and safety in developing pancreatic cancer treatments throughout the region. Regulatory bodies are working towards expediting the approval process for new therapies, facilitating timely access to cutting-edge treatments for patients in the Asia Pacific region. Additionally, regulations promote transparency and fair competition among market players, which ultimately benefits consumers by offering a wider range of treatment options at competitive prices. These elements are boosting the regional growth.

Key players in the market

Some of the key players in Pancreatic Cancer market include Celgene Corporation, F. Hoffmann-La Roche AG, Midatech Pharma PLC, Eli Lilly and Company, Sun BioPharma, Inc, Oncolytics Biotech, Clovis Oncology, Polaris Pharmaceuticals, Inc, Pharmacyte Biotech Inc and Novartis International AG.

Key Developments:

In March 2023, Novartis is currently in Phase I of the clinical development of LGK-974 for metastatic pancreatic cancer. The phase transition success rate (PTSR) benchmark for moving into Phase II for Phase I drugs for Metastatic Pancreatic Cancer is 88%, according to GlobalData.

In December 2022, scientists developed the world's first early pancreatic cancer screening test, which utilizes worms to discover tumors. The test, which was initiated in Japan this month, claims to be 100% precise in detecting cancer and can trace it in its early stages.

In October 2022, Erasca, based extended its current collaboration with Pfizer to evaluate ERAS-007 when combined with Pfizer's Ibrance (palbociclib). Both biopharma will start clinical proof-of-concept research as part of the extended clinical trial collaboration and supply agreement.

In February 2022, A partnership between Eli Lilly and Company and UNICEF was announced with the goal of enhancing healthcare resources for the roughly 10 million children and adolescents with non-communicable diseases.

Treatment Types Covered:

• Radiation Therapy
• Targeted Drug Therapy
• Immunotherapy
• Chemotherapy
• Other Treatment Types

Diagnostic Tools Covered:

• Computerized Tomography (CT) Scans
• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET) Scans
• Other Diagnostic Tools

End Users Covered:

• Diagnostic Laboratories
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Pancreatic Cancer Market, By Treatment Type

• 5.1 Introduction
• 5.2 Radiation Therapy
• 5.3 Targeted Drug Therapy
• 5.4 Immunotherapy
• 5.5 Chemotherapy
• 5.6 Other Treatment Types

6 Global Pancreatic Cancer Market, By Diagnostic Tool

• 6.1 Introduction
• 6.2 Computerized Tomography (CT) Scans
• 6.3 Magnetic Resonance Imaging (MRI)
• 6.4 Positron Emission Tomography (PET) Scans
• 6.5 Other Diagnostic Tools

7 Global Pancreatic Cancer Market, By End User

• 7.1 Introduction
• 7.2 Diagnostic Laboratories
• 7.3 Hospitals
• 7.4 Other End Users

8 Global Pancreatic Cancer Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Celgene Corporation
• 10.2 F. Hoffmann-La Roche AG
• 10.3 Midatech Pharma PLC
• 10.4 Eli Lilly and Company
• 10.5 Sun BioPharma, Inc
• 10.6 Oncolytics Biotech
• 10.7 Clovis Oncology
• 10.8 Polaris Pharmaceuticals, Inc
• 10.9 Pharmacyte Biotech Inc
• 10.10 Novartis International AG